StreetInsider.com News Articles

CapsoVision to Present at the 20th Annual LD Micro Main Event

Tue, 13 Oct 2026 16:05:00 -0400

SARATOGA, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will present at the 20th Annual LD Micro Main Event, taking place October 19-21, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Format: Company Presentation and 1x1 Investor Meetings

Date/Time: Wednesday, October 21, 2026, at 9:00–9:25 am PT

A webcast of

CapsoVision to Present at the 20th Annual LD Micro Main Event

Tue, 13 Oct 2026 16:05:00 -0400

Format: Company Presentation and 1x1 Investor Meetings

Date/Time: Wednesday, October 21, 2026, at 9:00–9:25 am PT

A webcast of

Form 8-K CapsoVision, Inc For: Sep 25

Mon, 28 Sep 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260928/27111850.html

CapsoVision wins FDA clearance for AI reading tool in capsule endoscopy

Mon, 28 Sep 2026 09:01:06 -0400

CapsoVision, Inc. (NASDAQ: CV) announced that its AI Highlights tool for the CapsoCam Plus capsule endoscopy system received clearance from the U.S. Food and Drug Administration on September 25, 2026.

AI Highlights is designed to assist physicians in reviewing small bowel capsule endoscopy studies in adult and pediatric patients over two years of age where the procedure was performed due to suspected small bowel bleeding. The tool identifies and marks images containing suspected abnormal lesions, prioritizing them for physician review with the goal of reducing overall review time.

The tool integrates with CapsoVision's CapsoView video processing and review software and supports workflows

CapsoVision wins FDA clearance for AI reading tool in capsule endoscopy

Mon, 28 Sep 2026 09:01:06 -0400

The tool integrates with CapsoVision's CapsoView video processing and review software and supports workflows

CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®

Mon, 28 Sep 2026 09:00:00 -0400

SARATOGA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that AI Highlights™, its AI-assisted reading tool for the CapsoCam Plus system, received clearance from the U.S. Food and Drug Administration (FDA) on September 25, 2026.

AI Highlights is designed to support physicians in the review of small bowel capsule endoscopy studies collected from adult and pediatric patients (over two years of age) in whom the study was performed due to suspected small bowel bleeding, specifically to reduce the time

CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®

Mon, 28 Sep 2026 09:00:00 -0400

Form 4 CapsoVision, Inc For: Sep 18 Filed by: HARARI ELIYAHOU ET AL

Wed, 23 Sep 2026 21:02:00 -0400

si-local-file:///var/storage/secattach/20260923/27097744.html

Form 4/A CapsoVision, Inc For: Apr 17 Filed by: Shen Ching Hang

Wed, 23 Sep 2026 18:54:00 -0400

si-local-file:///var/storage/secattach/20260923/27097633.html

Form 4/A CapsoVision, Inc For: Sep 15 Filed by: Shen Ching Hang

Wed, 23 Sep 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260923/27097495.html

Form 4 CapsoVision, Inc For: Sep 15 Filed by: Shen Ching Hang

Fri, 18 Sep 2026 18:15:00 -0400

si-local-file:///var/storage/secattach/20260918/27081446.html

Form 8-K CapsoVision, Inc For: Sep 17

Fri, 18 Sep 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260918/27080609.html

Form 424B5 CapsoVision, Inc

Fri, 18 Sep 2026 14:34:00 -0400

si-local-file:///var/storage/secattach/20260918/27080156.html

Roth/MKM Starts CapsoVision Inc (CV) at Buy

Fri, 28 Aug 2026 07:07:29 -0400

Roth/MKM analyst Kevin Holder initiates coverage on CapsoVision Inc (NASDAQ: CV) with a Buy rating and a price target of $9.00.

For an analyst ratings summary and ratings history on CapsoVision Inc click here. For more ratings news on CapsoVision Inc click here.

Shares of CapsoVision Inc closed at $6.06 yesterday.

Titan Partners Starts CapsoVision Inc (CV) at Buy

Wed, 26 Aug 2026 07:05:00 -0400

Titan Partners initiates coverage on CapsoVision Inc (NASDAQ: CV) with a Buy rating and a price target of $10.00.

For an analyst ratings summary and ratings history on CapsoVision Inc click here. For more ratings news on CapsoVision Inc click here.

Shares of CapsoVision Inc closed at $5.85 yesterday.

Form EFFECT CapsoVision, Inc

Mon, 24 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26963773.html

Form EFFECT CapsoVision, Inc

Mon, 24 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26963773.html

Form 424B5 CapsoVision, Inc

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961813.html

Form 424B5 CapsoVision, Inc

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961813.html

Form 8-K CapsoVision, Inc For: Aug 13

Tue, 18 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260818/26939906.html

Form 8-K CapsoVision, Inc For: Aug 13

Tue, 18 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260818/26939906.html

CapsoVision (CV) Reiterated at Speculative Buy by Benchmark

Fri, 14 Aug 2026 08:00:47 -0400

Benchmark analyst Bruce Jackson reiterated a Speculative Buy rating and $10.00 price target on CapsoVision Inc (NASDAQ: CV).

The analyst commented, "CapsoVision provided a 2Q update. Since launch, CapsoCam Plus has now been used in more than 176,000 procedures (up from 167,000 last quarter). Expectations for US FDA 510(k) clearance of the AI assisted reading feature for CapsoCam Plus slipped to the end of 3Q but the product will likely contribute to 4Q results. The European launch is starting now, and management remains encouraged by customer interest in the product. The 510(k) submission for CapsoCam Colon is now anticipated during 4Q

CapsoVision (CV) files $250M mixed shelf

Thu, 13 Aug 2026 16:54:11 -0400

CapsoVision (NASDAQ: CV) file $250,000,000 mixed shelf of:

Common Stock
Preferred Stock
Warrants
Rights
Units

CapsoVision (CV) files $250M mixed shelf

Thu, 13 Aug 2026 16:54:11 -0400

CapsoVision (NASDAQ: CV) file $250,000,000 mixed shelf of:

Common Stock
Preferred Stock
Warrants
Rights
Units

Form S-3 CapsoVision, Inc

Thu, 13 Aug 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260813/26922318.html